FRK plays an oncogenic role in non‐small cell lung cancer by enhancing the stemness phenotype <i>via</i> induction of metabolic reprogramming

Zhang, Li; Yang, Yongfeng; Chai, Li; Bu, Hong; Yang, Ying; Huang, Hong; Ran, Jingjing; Zhu, Yihan; Li, Li; Chen, Fei; Liu, Weimin

doi:10.1002/ijc.32530

Cited by 20 publications

(14 citation statements)

References 40 publications

(70 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present, the malignant phenotype of most tumor tissues is closely related to the metabolisms of special material and energy, such as oral cancer (Nakazato et al 2019), hepatocellular carcinoma (Fang et al 2019), pancreatic cancer (Yang et al 2019), non-small cell lung cancer (Zhang et al 2019), prostate cancer (Marin de Mas et al 2019), etc. Colorectal cancer (CRC) is the most frequent malignant gastrointestinal tumor and a leading cause of cancer death worldwide, along with an increase of about 150,000 cases every year (Jemal et al 2008).…”

Section: Introductionmentioning

confidence: 99%

AZGP1 suppresses the process of colorectal cancer after upregulating FASN expression via mTOR signal pathway

Yu¹,

Ling²,

Yu³

et al. 2020

gpb

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the most common malignant gastrointestinal tumor. Obesity has been confirmed to be closely related to the occurrence of CRC, but the specific mechanism is not clear. This study mainly explored the roles of obesity-related genes, fatty acid synthase (FASN) and zinc-alpha-2-glycoprotein (AZGP1) in CRC. 30 cases of CRC tissues and adjacent normal colorectal tissues were obtained to quantify the levels of FASN and AZGP1 using qRT-PCR and Western blotting. Overexpression-AZGP1, overexpression-FASN and FASN shRNA were transfected into SW480 cells. CCK-8, wound healing and transwell assays were used to evaluate the roles of FASN and AZGP1 on cell proliferation, migration as well as invasion. Western blot was performed to investigate the expression of MMP-2, MMP-9 and mTOR signaling-related proteins. AZGP1 expression was decreased in CRC tissues, which was negatively correlated with FASN expression. Overexpression-AZGP1 showed a significant inhibitory effect on cell proliferation, invasion and migration via inhibiting MMP-2 and MMP-9 expressions. Furthermore, up-regulation of AZGP1 suppressed the expression of mTOR pathway downstream proteins 4EBP and eIF4E through inhibiting FASN expression. Reintroduction of overexpression-FASN could partially reverse and inhibition of FASN further decrease the antitumor effect of AZGP1. AZGP1 suppresses CRC cellular activities by regulating FASN via mTOR pathway, suggesting that AZGP1 and FASN may be the targets for CRC therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

AZGP1 suppresses the process of colorectal cancer after upregulating FASN expression via mTOR signal pathway

Yu¹,

Ling²,

Yu³

et al. 2020

gpb

View full text Add to dashboard Cite

show abstract

“…Zhou et al found that A549 cells secrete SEMA3A to inhibit the maturation and functions of dendritic cells, which might be associated with the unidenti ed mechanism of immune evasion by tumor cells [52]. Interestingly, FRK was considered to be a underlying treatment target for drug discovery, as it has a carcinogenic effect in lung cancer cells via inducing metabolic reprogramming and nally promoting epithelial-mesenchymal transition and metastasis [53]. TOMM6 is an upregulated mRNA-related lncRNA UCA1 that might affect cisplatin resistance in LUAD [54].…”

Section: Discussionmentioning

confidence: 99%

Potential Therapeutic Value of Mangiferin for Lung Adenocarcinoma (Luad): A Comprehensive Study Based on in Vitro Experiments and Bioinformatics

Liu

Chi

Meng

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Lung adenocarcinoma (LUAD), which is the most common lung cancer type in never-smokers and primarily occurs in women, requires effective treatment methods. Mangiferin is a polyphenol widely found in mango trees and has been reported to have chemotherapeutic and preventive potential against various types of cancer. Thus, we investigated the potential therapeutic value of mangiferin for LUAD.Methods: Cell lines A549, H2030 and H1299 were processed with mangiferin to detect and screen for differentially expressed lncRNAs and mRNAs. Close associations between extracted common lncRNAs and mRNAs were identified for lncRNA-mRNA network construction. Based on the network and an online database, target lncRNAs, target genes and meaningful lncRNA-mRNA pairs were identified, and signaling pathway analysis was performed.Results: The top 200 lncRNA-mRNA pairs were used to construct the network. We identified 12 target lncRNAs and 18 target genes. Gene nodes in the network were mostly visualized on the PI3K-Akt signaling pathway (P < 0.01). Furthermore, lncRNA-mRNA pairs that contained the genes ARHGAP29, BRIX1, CD109, CDK1, CTNNAL1, DAB2IP, DDIT4L, GPR162, ICAM5, KCNAB3 and MMP7 were considered to be meaningful lncRNA-mRNA pairs affected by mangiferin in LUAD.Conclusions: Our study provided a comprehensive understanding of the potential therapeutic value of mangiferin for LUAD.

show abstract

“…In turn, in yet another sarcoma study, complete knockout of ORF57 was achieved in iSLK/Bac16 and HEK293/Bac36 cells, simultaneously expressing one Cas9 protein and two guide RNAs associated by several rounds of single-cell cloning and cell selection from a single vector [ 30 ]. In a further trial, researchers investigated the role of the FRK oncogene in the H1299 lung cancer cell line, demonstrating that knockout of FRK suppressed epithelial to mesenchymal transition cell colony formation and proliferation of cancer cells [ 31 ]. In turn, in a study concerning canine cancer research, knockout of one of the main tumor suppressor genes, TP53, was rescued by administration of TP53 gRNA, resulting in in vivo and in vitro non-cancerous phenotypes [ 32 ].…”

Section: Applications and Advances Of The Crispr/cas9 Technique Inmentioning

confidence: 99%

CRISPR/Cas9 in Cancer Immunotherapy: Animal Models and Human Clinical Trials

Khalaf

Janowicz

Dyszkiewicz-Konwińska

et al. 2020

Genes

View full text Add to dashboard Cite

Even though chemotherapy and immunotherapy emerged to limit continual and unregulated proliferation of cancer cells, currently available therapeutic agents are associated with high toxicity levels and low success rates. Additionally, ongoing multi-targeted therapies are limited only for few carcinogenesis pathways, due to continually emerging and evolving mutations of proto-oncogenes and tumor-suppressive genes. CRISPR/Cas9, as a specific gene-editing tool, is used to correct causative mutations with minimal toxicity, but is also employed as an adjuvant to immunotherapy to achieve a more robust immunological response. Some of the most critical limitations of the CRISPR/Cas9 technology include off-target mutations, resulting in nonspecific restrictions of DNA upstream of the Protospacer Adjacent Motifs (PAM), ethical agreements, and the lack of a scientific consensus aiming at risk evaluation. Currently, CRISPR/Cas9 is tested on animal models to enhance genome editing specificity and induce a stronger anti-tumor response. Moreover, ongoing clinical trials use the CRISPR/Cas9 system in immune cells to modify genomes in a target-specific manner. Recently, error-free in vitro systems have been engineered to overcome limitations of this gene-editing system. The aim of the article is to present the knowledge concerning the use of CRISPR Cas9 technique in targeting treatment-resistant cancers. Additionally, the use of CRISPR/Cas9 is aided as an emerging supplementation of immunotherapy, currently used in experimental oncology. Demonstrating further, applications and advances of the CRISPR/Cas9 technique are presented in animal models and human clinical trials. Concluding, an overview of the limitations of the gene-editing tool is proffered.

show abstract

FRK plays an oncogenic role in non‐small cell lung cancer by enhancing the stemness phenotype via induction of metabolic reprogramming

Cited by 20 publications

References 40 publications

AZGP1 suppresses the process of colorectal cancer after upregulating FASN expression via mTOR signal pathway

AZGP1 suppresses the process of colorectal cancer after upregulating FASN expression via mTOR signal pathway

Potential Therapeutic Value of Mangiferin for Lung Adenocarcinoma (Luad): A Comprehensive Study Based on in Vitro Experiments and Bioinformatics

CRISPR/Cas9 in Cancer Immunotherapy: Animal Models and Human Clinical Trials

Contact Info

Product

Resources

About